

# Joanna L Elson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9577401/publications.pdf>

Version: 2024-02-01

77  
papers

3,653  
citations

186265

28  
h-index

138484

58  
g-index

81  
all docs

81  
docs citations

81  
times ranked

4470  
citing authors

#	ARTICLE	IF	CITATIONS
1	Reduced-Median-Network Analysis of Complete Mitochondrial DNA Coding-Region Sequences for the Major African, Asian, and European Haplogroups. <i>American Journal of Human Genetics</i> , 2002, 70, 1152-1171.	6.2	482
2	Strong Purifying Selection in Transmission of Mammalian Mitochondrial DNA. <i>PLoS Biology</i> , 2008, 6, e10.	5.6	425
3	Mitochondrial DNA and survival after sepsis: a prospective study. <i>Lancet, The</i> , 2005, 366, 2118-2121.	13.7	162
4	Assigning pathogenicity to mitochondrial tRNA mutations: when "definitely maybe" is not good enough. <i>Trends in Genetics</i> , 2004, 20, 591-596.	6.7	159
5	A comparative analysis approach to determining the pathogenicity of mitochondrial tRNA mutations. <i>Human Mutation</i> , 2011, 32, 1319-1325.	2.5	159
6	Purifying selection of mtDNA and its implications for understanding evolution and mitochondrial disease. <i>Nature Reviews Genetics</i> , 2008, 9, 657-662.	16.3	155
7	Mitochondrial tRNA mutations and disease. <i>Wiley Interdisciplinary Reviews RNA</i> , 2010, 1, 304-324.	6.4	145
8	Nature of Mitochondrial DNA Deletions in Substantia Nigra Neurons. <i>American Journal of Human Genetics</i> , 2008, 82, 228-235.	6.2	123
9	Clonal Expansion of Early to Mid-Life Mitochondrial DNA Point Mutations Drives Mitochondrial Dysfunction during Human Ageing. <i>PLoS Genetics</i> , 2014, 10, e1004620.	3.5	115
10	Cellular bioenergetics is impaired in patients with chronic fatigue syndrome. <i>PLoS ONE</i> , 2017, 12, e0186802.	2.5	106
11	Does the mitochondrial genome play a role in the etiology of Alzheimer's disease?. <i>Human Genetics</i> , 2006, 119, 241-254.	3.8	102
12	Deep-brain stimulation associates with improved microvascular integrity in the subthalamic nucleus in Parkinson's disease. <i>Neurobiology of Disease</i> , 2015, 74, 392-405.	4.4	86
13	mtDNA mutations and common neurodegenerative disorders. <i>Trends in Genetics</i> , 2005, 21, 583-586.	6.7	78
14	Mitochondrial DNA disease: new options for prevention. <i>Human Molecular Genetics</i> , 2011, 20, R168-R174.	2.9	72
15	Perceived fatigue is highly prevalent and debilitating in patients with mitochondrial disease. <i>Neuromuscular Disorders</i> , 2015, 25, 563-566.	0.6	67
16	Comparison of Mitochondrial Mutation Spectra in Ageing Human Colonic Epithelium and Disease: Absence of Evidence for Purifying Selection in Somatic Mitochondrial DNA Point Mutations. <i>PLoS Genetics</i> , 2012, 8, e1003082.	3.5	61
17	Mitochondrial DNA clonality in the dock: can surveillance swing the case?. <i>Trends in Genetics</i> , 2006, 22, 603-607.	6.7	56
18	Mitochondrial Abnormality Associates with Type-Specific Neuronal Loss and Cell Morphology Changes in the Pedunculo-pontine Nucleus in Parkinson Disease. <i>American Journal of Pathology</i> , 2013, 183, 1826-1840.	3.8	53

#	ARTICLE	IF	CITATIONS
19	Pathogenic mitochondrial tRNA mutations - Which mutations are inherited and why?. <i>Human Mutation</i> , 2009, 30, E984-E992.	2.5	49
20	An animal model mimicking pedunclopontine nucleus cholinergic degeneration in Parkinson's disease. <i>Brain Structure and Function</i> , 2015, 220, 479-500.	2.3	49
21	Mitochondrial DNA changes in pedunclopontine cholinergic neurons in Parkinson disease. <i>Annals of Neurology</i> , 2017, 82, 1016-1021.	5.3	45
22	African Haplogroup L mtDNA Sequences Show Violations of Clock-like Evolution. <i>Molecular Biology and Evolution</i> , 2004, 21, 1843-1854.	8.9	43
23	Relationship Between Mitochondria and $\alpha$ -Synuclein. <i>Archives of Neurology</i> , 2012, 69, 385.	4.5	43
24	Pharmacogenetic stimulation of cholinergic pedunclopontine neurons reverses motor deficits in a rat model of Parkinson's disease. <i>Molecular Neurodegeneration</i> , 2015, 10, 47.	10.8	41
25	Habitual Physical Activity in Mitochondrial Disease. <i>PLoS ONE</i> , 2011, 6, e22294.	2.5	37
26	The role of the mitochondrial ribosome in human disease: searching for mutations in 12S mitochondrial rRNA with high disruptive potential. <i>Human Molecular Genetics</i> , 2014, 23, 949-967.	2.9	35
27	Relative Rates of Evolution in the Coding and Control Regions of African mtDNAs. <i>Molecular Biology and Evolution</i> , 2007, 24, 2213-2221.	8.9	33
28	Characterization of mtDNA variation in a cohort of South African paediatric patients with mitochondrial disease. <i>European Journal of Human Genetics</i> , 2012, 20, 650-656.	2.8	30
29	Mitochondrial DNA as a Risk Factor for False Positives in Case-Control Association Studies. <i>Journal of Genetics and Genomics</i> , 2015, 42, 169-172.	3.9	30
30	The presence of highly disruptive 16S rRNA mutations in clinical samples indicates a wider role for mutations of the mitochondrial ribosome in human disease. <i>Mitochondrion</i> , 2015, 25, 17-27.	3.4	29
31	A proposed consensus panel of organisms for determining evolutionary conservation of mt-tRNA point mutations. <i>Mitochondrion</i> , 2012, 12, 533-538.	3.4	28
32	The low abundance of clonally expanded mitochondrial DNA point mutations in aged substantia nigra neurons. <i>Aging Cell</i> , 2009, 8, 496-498.	6.7	26
33	Aggregation, impaired degradation and immunization targeting of amyloid-beta dimers in Alzheimer's disease: a stochastic modelling approach. <i>Molecular Neurodegeneration</i> , 2012, 7, 32.	10.8	25
34	Design and evaluation of bi-functional iron chelators for protection of dopaminergic neurons from toxicants. <i>Archives of Toxicology</i> , 2020, 94, 3105-3123.	4.2	24
35	The effect of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) severity on cellular bioenergetic function. <i>PLoS ONE</i> , 2020, 15, e0231136.	2.5	24
36	Mitochondrial complex activity in permeabilised cells of chronic fatigue syndrome patients using two cell types. <i>PeerJ</i> , 2019, 7, e6500.	2.0	24

#	ARTICLE	IF	CITATIONS
37	MtDNA population variation in Myalgic encephalomyelitis/Chronic fatigue syndrome in two populations: a study of mildly deleterious variants. <i>Scientific Reports</i> , 2019, 9, 2914.	3.3	21
38	The length of cytochrome c oxidase-negative segments in muscle fibres in patients with mtDNA myopathy. <i>Neuromuscular Disorders</i> , 2002, 12, 858-864.	0.6	20
39	Using MutPred derived mtDNA load scores to evaluate mtDNA variation in hypertension and diabetes in a two-population cohort: The SABPA study. <i>Journal of Genetics and Genomics</i> , 2017, 44, 139-149.	3.9	20
40	The unresolved role of mitochondrial DNA in Parkinson's disease: An overview of published studies, their limitations, and future prospects. <i>Neurochemistry International</i> , 2019, 129, 104495.	3.8	19
41	MutPred mutational load analysis shows mildly deleterious mitochondrial DNA variants are not more prevalent in Alzheimer's patients, but may be under-represented in healthy older individuals. <i>Mitochondrion</i> , 2017, 34, 141-146.	3.4	18
42	Mitochondrial DNA sequence context in the penetrance of mitochondrial t-RNA mutations: A study across multiple lineages with diagnostic implications. <i>PLoS ONE</i> , 2017, 12, e0187862.	2.5	18
43	DREADD Activation of Pedunculopontine Cholinergic Neurons Reverses Motor Deficits and Restores Striatal Dopamine Signaling in Parkinsonian Rats. <i>Neurotherapeutics</i> , 2020, 17, 1120-1141.	4.4	18
44	Does mitochondrial DNA predispose to neuromyelitis optica (Devic's disease)?. <i>Brain</i> , 2008, 131, e93-e93.	7.6	17
45	Pedunculopontine cell loss and protein aggregation direct microglia activation in parkinsonian rats. <i>Brain Structure and Function</i> , 2016, 221, 2319-2341.	2.3	17
46	Associating Mitochondrial DNA Variation with Complex Traits. <i>American Journal of Human Genetics</i> , 2007, 80, 378-382.	6.2	16
47	A new approach to find biomarkers in chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) by single-cell Raman micro-spectroscopy. <i>Analyst</i> , The, 2019, 144, 913-920.	3.5	16
48	Clinically proven mtDNA mutations are not common in those with chronic fatigue syndrome. <i>BMC Medical Genetics</i> , 2017, 18, 29.	2.1	15
49	The aetiology of cardiovascular disease: a role for mitochondrial DNA?. <i>Cardiovascular Journal of Africa</i> , 2018, 29, 122-132.	0.4	14
50	Mitochondrial DNA haplogroups and amyotrophic lateral sclerosis. <i>Neurogenetics</i> , 2007, 8, 65-67.	1.4	13
51	New mtDNA Association Model, MutPred Variant Load, Suggests Individuals With Multiple Mildly Deleterious mtDNA Variants Are More Likely to Suffer From Atherosclerosis. <i>Frontiers in Genetics</i> , 2018, 9, 702.	2.3	12
52	Panel-Based Nuclear and Mitochondrial Next-Generation Sequencing Outcomes of an Ethnically Diverse Pediatric Patient Cohort with Mitochondrial Disease. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 503-513.	2.8	12
53	Testing the adaptive selection of human mtDNA haplogroups: an experimental bioenergetics approach. <i>Biochemical Journal</i> , 2007, 404, e3-5.	3.7	10
54	Haplogroup Context is Less Important in the Penetrance of Mitochondrial DNA Complex I Mutations Compared to mt-tRNA Mutations. <i>Journal of Molecular Evolution</i> , 2018, 86, 395-403.	1.8	10

#	ARTICLE	IF	CITATIONS
55	Mitochondrial DNA mutations induce mitochondrial biogenesis and increase the tumorigenic potential of Hodgkin and Reed-Sternberg cells. <i>Carcinogenesis</i> , 2020, 41, 1735-1745.	2.8	10
56	Heterologous Inferential Analysis (HIA) as a Method to Understand the Role of Mitochondrial rRNA Mutations in Pathogenesis. <i>Methods in Molecular Biology</i> , 2015, 1264, 369-383.	0.9	10
57	Assessing cellular energy dysfunction in CFS/ME using a commercially available laboratory test. <i>Scientific Reports</i> , 2019, 9, 11464.	3.3	9
58	Toward a mtDNA locus-specific mutation database using the LOVD platform. <i>Human Mutation</i> , 2012, 33, 1352-1358.	2.5	8
59	Altered motor, anxiety-related and attentional task performance at baseline associate with multiple gene copies of the vesicular acetylcholine transporter and related protein overexpression in ChAT::Cre+ rats. <i>Brain Structure and Function</i> , 2019, 224, 3095-3116.	2.3	8
60	Substrate utilisation of cultured skeletal muscle cells in patients with CFS. <i>Scientific Reports</i> , 2020, 10, 18232.	3.3	8
61	Novel 1-hydroxypyridin-2-one metal chelators prevent and rescue ubiquitin proteasomal-related neuronal injury in an in vitro model of Parkinson's disease. <i>Archives of Toxicology</i> , 2020, 94, 813-831.	4.2	8
62	Mitochondrial DNA variation in Parkinson's disease: Analysis of out-of-place population variants as a risk factor. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	3.4	7
63	Raising Doubts about the Pathogenicity of Mitochondrial DNA Mutation m.3308T>C in Left Ventricular Hypertraveculation/Noncompaction. <i>Cardiology</i> , 2012, 122, 113-115.	1.4	6
64	Temporal-Spatial Profiling of Pedunculopontine Galanin-Cholinergic Neurons in the Lactacystin Rat Model of Parkinson's Disease. <i>Neurotoxicity Research</i> , 2018, 34, 16-31.	2.7	6
65	The role of mitochondria in ME/CFS: a perspective. <i>Fatigue: Biomedicine, Health and Behavior</i> , 2019, 7, 52-58.	1.9	6
66	Call for participation in the neurogenetics consortium within the Human Variome Project. <i>Neurogenetics</i> , 2011, 12, 169-173.	1.4	5
67	What can a comparative genomics approach tell us about the pathogenicity of mtDNA mutations in human populations?. <i>Evolutionary Applications</i> , 2019, 12, 1912-1930.	3.1	5
68	A broad comparative genomics approach to understanding the pathogenicity of Complex I mutations. <i>Scientific Reports</i> , 2021, 11, 19578.	3.3	5
69	Could we offer mitochondrial donation or similar assisted reproductive technology to South African patients with mitochondrial DNA disease?. <i>South African Medical Journal</i> , 2016, 106, 234.	0.6	4
70	Heterologous Inferential Analysis (HIA) and Other Emerging Concepts: In Understanding Mitochondrial Variation In Pathogenesis: There is no More Low-Hanging Fruit. <i>Methods in Molecular Biology</i> , 2021, 2277, 203-245.	0.9	4
71	Older mothers are not at risk of having grandchildren with sporadic mtDNA deletions. <i>Genetics in Medicine</i> , 2010, 12, 313-314.	2.4	3
72	Implementing a new variant load model to investigate the role of mtDNA in oxidative stress and inflammation in a bi-ethnic cohort: the SABPA study. <i>Mitochondrial DNA Part A: DNA Mapping, Sequencing, and Analysis</i> , 2019, 30, 440-447.	0.7	3

#	ARTICLE	IF	CITATIONS
73	Evolutionary dissection of mtDNA hg H: a susceptibility factor for hypertrophic cardiomyopathy. Mitochondrial DNA Part A: DNA Mapping, Sequencing, and Analysis, 2020, 31, 238-244.	0.7	3
74	Investigation of the correlation between mildly deleterious mtDNA Variations and the clinical progression of multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 53, 103055.	2.0	3
75	Mitochondrial DNA copy number is not associated with fatigue status in Primary Sjögren's Syndrome. Fatigue: Biomedicine, Health and Behavior, 2018, 6, 123-131.	1.9	2
76	Single-Cell Approaches for Studying the Role of Mitochondrial DNA in Neurodegenerative Disease. Methods in Molecular Biology, 2021, 2277, 299-329.	0.9	1
77	Common mtDNA Polymorphisms and Neurodegenerative Disorders. , 2012, , 63-78.		0